358 related articles for article (PubMed ID: 28322294)
1. Effects of dipeptidyl peptidase-4 inhibitors on beta-cell function and insulin resistance in type 2 diabetes: meta-analysis of randomized controlled trials.
Lyu X; Zhu X; Zhao B; Du L; Chen D; Wang C; Liu G; Ran X
Sci Rep; 2017 Mar; 7():44865. PubMed ID: 28322294
[TBL] [Abstract][Full Text] [Related]
2. The effects of incretin-based therapies on β-cell function and insulin resistance in type 2 diabetes: A systematic review and network meta-analysis combining 360 trials.
Wu S; Gao L; Cipriani A; Huang Y; Yang Z; Yang J; Yu S; Zhang Y; Chai S; Zhang Z; Sun F; Zhan S
Diabetes Obes Metab; 2019 Apr; 21(4):975-983. PubMed ID: 30536884
[TBL] [Abstract][Full Text] [Related]
3. Comparisons between dipeptidyl peptidase-4 inhibitors and other classes of hypoglycemic drugs using two distinct biomarkers of pancreatic beta-cell function: A meta-analysis.
Takahashi M; Shibasaki M; Echizen H; Kushiyama A
PLoS One; 2020; 15(7):e0236603. PubMed ID: 32706828
[TBL] [Abstract][Full Text] [Related]
4. Comparisons of the efficacy of glucose control, lipid profile, and β-cell function between DPP-4 inhibitors and AGI treatment in type 2 diabetes patients: a meta-analysis.
Cai X; Yang W; Zhou L; Zhang S; Han X; Ji L
Endocrine; 2015 Dec; 50(3):590-7. PubMed ID: 26048437
[TBL] [Abstract][Full Text] [Related]
5. The Effects of Novel Antidiabetic Drugs on Albuminuria in Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
Luo Y; Lu K; Liu G; Wang J; Laurent I; Zhou X
Clin Drug Investig; 2018 Dec; 38(12):1089-1108. PubMed ID: 30255388
[TBL] [Abstract][Full Text] [Related]
6. Combination therapy of dipeptidyl peptidase-4 inhibitors and metformin in type 2 diabetes: rationale and evidence.
Liu Y; Hong T
Diabetes Obes Metab; 2014 Feb; 16(2):111-7. PubMed ID: 23668534
[TBL] [Abstract][Full Text] [Related]
7. Impact of sitagliptin on markers of beta-cell function: a meta-analysis.
Riche DM; East HE; Riche KD
Am J Med Sci; 2009 May; 337(5):321-8. PubMed ID: 19322069
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of dipeptidyl-peptidase-4 inhibitors and impact on β-cell function in Asian and Caucasian type 2 diabetes mellitus patients: A meta-analysis.
Cai X; Han X; Luo Y; Ji L
J Diabetes; 2015 May; 7(3):347-59. PubMed ID: 25043156
[TBL] [Abstract][Full Text] [Related]
9. Short-term and long-term effects of dipeptidyl peptidase-4 inhibitors in type 2 diabetes mellitus patients with renal impairment: a meta-analysis of randomized controlled trials.
Li R; Wang R; Li H; Sun S; Zou M; Cheng G
Diabetes Metab Res Rev; 2016 Sep; 32(6):460-9. PubMed ID: 26433213
[TBL] [Abstract][Full Text] [Related]
10. Efficacy, safety and impact on β-cell function of dipeptidyl peptidase-4 inhibitors plus metformin combination therapy in patients with type 2 diabetes and the difference between Asians and Caucasians: a meta-analysis.
Gao W; Wang Q; Yu S
J Endocrinol Invest; 2016 Sep; 39(9):1061-74. PubMed ID: 27072669
[TBL] [Abstract][Full Text] [Related]
11. Effects of Dipeptidyl Peptidase-4 Inhibitors on Renal Outcomes in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis.
Bae JH; Kim S; Park EG; Kim SG; Hahn S; Kim NH
Endocrinol Metab (Seoul); 2019 Mar; 34(1):80-92. PubMed ID: 30912341
[TBL] [Abstract][Full Text] [Related]
12. Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on beta-cell function in patients with type 2 diabetes: a model-based approach.
Xu L; Man CD; Charbonnel B; Meninger G; Davies MJ; Williams-Herman D; Cobelli C; Stein PP
Diabetes Obes Metab; 2008 Dec; 10(12):1212-20. PubMed ID: 18476982
[TBL] [Abstract][Full Text] [Related]
13. The effects of dipeptidyl peptidase-4 inhibitors on bone fracture among patients with type 2 diabetes mellitus: A network meta-analysis of randomized controlled trials.
Yang J; Huang C; Wu S; Xu Y; Cai T; Chai S; Yang Z; Sun F; Zhan S
PLoS One; 2017; 12(12):e0187537. PubMed ID: 29206832
[TBL] [Abstract][Full Text] [Related]
14. Effects of dipeptidyl peptidase-4 inhibitors on blood pressure in patients with type 2 diabetes: A systematic review and meta-analysis.
Zhang X; Zhao Q
J Hypertens; 2016 Feb; 34(2):167-75. PubMed ID: 26682782
[TBL] [Abstract][Full Text] [Related]
15. Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysis.
Gooßen K; Gräber S
Diabetes Obes Metab; 2012 Dec; 14(12):1061-72. PubMed ID: 22519906
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of DPP-4 inhibitors in patients with type 2 diabetes: Meta-analysis of placebo-controlled randomized clinical trials.
Rehman MB; Tudrej BV; Soustre J; Buisson M; Archambault P; Pouchain D; Vaillant-Roussel H; Gueyffier F; Faillie JL; Perault-Pochat MC; Cornu C; Boussageon R
Diabetes Metab; 2017 Feb; 43(1):48-58. PubMed ID: 27745828
[TBL] [Abstract][Full Text] [Related]
17. Evaluating second-line treatment options for type 2 diabetes: focus on secondary effects of GLP-1 agonists and DPP-4 inhibitors.
Boland CL; Degeeter M; Nuzum DS; Tzefos M
Ann Pharmacother; 2013 Apr; 47(4):490-505. PubMed ID: 23548652
[TBL] [Abstract][Full Text] [Related]
18. Meta-analysis of dipeptidyl peptidase-4 inhibitors use and cardiovascular risk in patients with type 2 diabetes mellitus.
Kaneko M; Narukawa M
Diabetes Res Clin Pract; 2016 Jun; 116():171-82. PubMed ID: 27321333
[TBL] [Abstract][Full Text] [Related]
19. Effect of dipeptidyl-peptidase-4 inhibitors on C-reactive protein in patients with type 2 diabetes: a systematic review and meta-analysis.
Liu X; Men P; Wang B; Cai G; Zhao Z
Lipids Health Dis; 2019 Jun; 18(1):144. PubMed ID: 31208420
[TBL] [Abstract][Full Text] [Related]
20. Effect of dipeptidyl peptidase-4 inhibitors on circulating tumor necrosis factor-α concentrations: A systematic review and meta-analysis of controlled trials.
Atkin SL; Katsiki N; Banach M; Mikhailidis DP; Pirro M; Sahebkar A
J Diabetes Complications; 2017 Sep; 31(9):1458-1464. PubMed ID: 28647512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
